Lupin to Commercialise Ranibizumab in Latin America

Lupin to commercialise ranibizumab in Latin America

Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin America.

McCann Joburg announces acquisition of specialist healthcare agency - African Marketing Confederation

@media screen and (max-width: 1024px) { .eael-hamburger--tablet { .eael-simple-menu-horizontal, .eael-simple-menu-vertical { display: none; } } .eael-hamburger--tablet { .eael-simple-menu-container .eael-simple-menu-toggle { display: block; } } } HOME ABOUT US AMC COMMITTEES MEMBERS EDUCATION CHARTERED MARKETER (AFRICA) SHORT COURSES NEWS & PUBLICATIONS NEWS ARTICLES PUBLICATIONS AMC CONFERENCE CONTACT US Hamburger Toggle Menu …

Lupin and SteinCares enter into License and Supply Agreement for Ranibizumab in Latin America - Express Pharma

Lupin announced that it has entered into a license and supply agreement with SteinCares, a specialty healthcare company in Latin America, for commercialisation of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialisation of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same. …

Lupin and SteinCares Enter into License and Supply Agreement for Ranibizumab in Latin America